^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFR C797S inhibitor

    Related drugs:
    5ms
    A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients (clinicaltrials.gov)
    P1/2, N=115, Not yet recruiting, Therapex Co., Ltd
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    TRX-221
    1year
    TRX-221, a novel 4th-generation EGFR inhibitor for overcoming C797S mutation-mediated acquired resistance in NSCLC (AACR 2023)
    With favorable DMPK profiles, once-daily oral dosing of TRX-221 induced strong anti-tumor effects in a dose-dependent manner in a variety of osimertinib-resistant CDX and PDX models. As a reversible, selective, and broad-spectrum 4th-generation EGFR-TKI, TRX-221 is currently undergoing IND-enabling studies and shows strong potential as a therapeutic solution to treat advanced NSCLC patients harboring EGFR mutations.
    Preclinical
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR wild-type • EGFR overexpression • EGFR C797S
    |
    Tagrisso (osimertinib) • TRX-221